{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:25:47Z","timestamp":1794673547535,"version":"4.9.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Artemisinin resistance has emerged and spread in the Greater Mekong Sub-region (GMS), followed by artemisinin-based combination therapy failure, due to both artemisinin and partner drug resistance. More worrying, artemisinin resistance has been recently reported and confirmed in Rwanda. Therefore, there is an urgent need to strengthen surveillance systems beyond the GMS to track the emergence or spread of artemisinin and partner drug resistance in other endemic settings. Currently, anti-malarial drug efficacy is monitored primarily through therapeutic efficacy studies (TES). Even though essential for anti-malarial drug policy change, these studies are difficult to conduct, expensive, and may not detect the early emergence of resistance. Additionally, results from TES may take years to be available to the stakeholders, jeopardizing their usefulness. Molecular markers are additional and useful tools to monitor anti-malarial drug resistance, as samples collected on dried blood spots are sufficient to monitor known and validated molecular markers of resistance, and could help detecting and monitoring the early emergence of resistance. However, molecular markers are not monitored systematically by national malaria control programmes, and are often assessed in research studies, but not in routine surveillance. The implementation of molecular markers as a routine tool for anti-malarial drug resistance surveillance could greatly improve surveillance of anti-malarial drug efficacy, making it possible to detect resistance before it translates to treatment failures. When possible, ex vivo assays should be included as their data could be useful complementary, especially when no molecular markers are validated.<\/jats:p>","DOI":"10.1186\/s12936-021-03942-5","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T07:28:37Z","timestamp":1634110117000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Time to scale up molecular surveillance for anti-malarial drug resistance in sub-saharan Africa"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6944-3892","authenticated-orcid":false,"given":"Christian","family":"Nsanzabana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,13]]},"reference":[{"key":"3942_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50\u20135.","journal-title":"Nature"},{"key":"3942_CR2","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1473-3099(15)00487-9","volume":"16","author":"C Amaratunga","year":"2016","unstructured":"Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis. 2016;16:357\u201365.","journal-title":"Lancet Infect Dis"},{"key":"3942_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12916-015-0539-5","volume":"13","author":"V Duru","year":"2015","unstructured":"Duru V, Khim N, Leang R, Kim S, Domergue A, Kloeung N, et al. Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations. BMC Med. 2015;13:305.","journal-title":"BMC Med"},{"key":"3942_CR4","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1128\/AAC.00835-15","volume":"59","author":"R Leang","year":"2015","unstructured":"Leang R, Taylor WR, Bouth DM, Song L, Tarning J, Char MC, et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in Western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother. 2015;59:4719\u201326.","journal-title":"Antimicrob Agents Chemother"},{"key":"3942_CR5","doi-asserted-by":"publisher","first-page":"e93138","DOI":"10.1371\/journal.pone.0093138","volume":"9","author":"C Lon","year":"2014","unstructured":"Lon C, Manning JE, Vanachayangkul P, So M, Sea D, Se Y, et al. Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trial. PLoS One. 2014;9:e93138.","journal-title":"PLoS One"},{"key":"3942_CR6","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1056\/NEJMc1403007","volume":"371","author":"DL Saunders","year":"2014","unstructured":"Saunders DL, Vanachayangkul P, Lon C, US Army Military Malaria Research Program, National Center for Parasitologym Entomology and Malaria Control. Royal Cambodian Armed Forces. Dihydroartemisinin-piperaquine failure in Cambodia. N Engl J Med. 2014;371:484\u20135.","journal-title":"N Engl J Med"},{"key":"3942_CR7","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S1473-3099(15)70049-6","volume":"15","author":"MD Spring","year":"2015","unstructured":"Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, et al. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis. 2015;15:683\u201391.","journal-title":"Lancet Infect Dis"},{"key":"3942_CR8","unstructured":"WHO. Status report on artemisinin resistance and ACT efficacy. Geneva, World Health Organization. 2018. https:\/\/www.who.int\/malaria\/publications\/atoz\/artemisinin-resistance-august2018\/en\/."},{"key":"3942_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s13149-016-0487-4","volume":"109","author":"B Witkowski","year":"2016","unstructured":"Witkowski B, Khim N, Kim S, Domergue A, Duru V, Menard D. Multiple and successive treatment failures in a patient infected by Plasmodium falciparum in Cambodia and treated by dihydroartemisinin-piperaquine (in French). Bull Soc Pathol Exot. 2016;109:87\u201390.","journal-title":"Bull Soc Pathol Exot"},{"key":"3942_CR10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3201\/eid2701.203527","volume":"27","author":"C Bergmann","year":"2021","unstructured":"Bergmann C, van Loon W, Habarugira F, Tacoli C, Jager JC, Savelsberg D, et al. Increase in kelch 13 polymorphisms in Plasmodium falciparum, Southern Rwanda. Emerg Infect Dis. 2021;27:294\u20136.","journal-title":"Emerg Infect Dis"},{"key":"3942_CR11","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana JM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602\u20138.","journal-title":"Nat Med"},{"key":"3942_CR12","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21:1120\u20138.","journal-title":"Lancet Infect Dis"},{"key":"3942_CR13","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization;\u00a02009. https:\/\/apps.who.int\/iris\/handle\/10665\/44048."},{"key":"3942_CR14","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/S1473-3099(20)30228-0","volume":"20","author":"M Imwong","year":"2020","unstructured":"Imwong M, Dhorda M, Myo Tun K, Thu AM, Phyo AP, Proux S, et al. Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. Lancet Infect Dis. 2020;20:1470\u201380.","journal-title":"Lancet Infect Dis"},{"key":"3942_CR15","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1473-3099(16)30415-7","volume":"17","author":"B Witkowski","year":"2017","unstructured":"Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study. Lancet Infect Dis. 2017;17:174\u201383.","journal-title":"Lancet Infect Dis"},{"key":"3942_CR16","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1073\/pnas.1615875114","volume":"114","author":"R Ataide","year":"2017","unstructured":"Ataide R, Ashley EA, Powell R, Chan JA, Malloy MJ, O\u2019Flaherty K, et al. Host immunity to Plasmodium falciparum and the assessment of emerging artemisinin resistance in a multinational cohort. Proc Natl Acad Sci USA. 2017;114:3515\u201320.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3942_CR17","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/infdis\/jix371","volume":"216","author":"R Ataide","year":"2017","unstructured":"Ataide R, Powell R, Moore K, McLean A, Phyo AP, Nair S, et al. Declining transmission and immunity to malaria and emerging artemisinin resistance in Thailand: a longitudinal study. J Infect Dis. 2017;216:723\u201331.","journal-title":"J Infect Dis"},{"key":"3942_CR18","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1093\/infdis\/jit082","volume":"207","author":"TM Lopera-Mesa","year":"2013","unstructured":"Lopera-Mesa TM, Doumbia S, Chiang S, Zeituni AE, Konate DS, Doumbouya M, et al. Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity. J Infect Dis. 2013;207:1655\u201363.","journal-title":"J Infect Dis"},{"key":"3942_CR19","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1098\/rspb.2002.2241","volume":"270","author":"NJ White","year":"2003","unstructured":"White NJ, Pongtavornpinyo W. The de novo selection of drug-resistant malaria parasites. Proc Biol Sci. 2003;270:545\u201354.","journal-title":"Proc Biol Sci"},{"key":"3942_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/1475-2875-8-253","volume":"8","author":"NJ White","year":"2009","unstructured":"White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Stepniewska K, et al. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J. 2009;8:253.","journal-title":"Malar J"},{"key":"3942_CR21","doi-asserted-by":"publisher","first-page":"e1008577","DOI":"10.1371\/journal.pcbi.1008577","volume":"17","author":"AOB Whitlock","year":"2021","unstructured":"Whitlock AOB, Juliano JJ, Mideo N. Immune selection suppresses the emergence of drug resistance in malaria parasites but facilitates its spread. PLoS Comput Biol. 2021;17:e1008577.","journal-title":"PLoS Comput Biol"},{"key":"3942_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1086\/504687","volume":"194","author":"AM McCollum","year":"2006","unstructured":"McCollum AM, Poe AC, Hamel M, Huber C, Zhou Z, Shi YP, et al. Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles. J Infect Dis. 2006;194:189\u201397.","journal-title":"J Infect Dis"},{"key":"3942_CR23","doi-asserted-by":"publisher","first-page":"e1000830","DOI":"10.1371\/journal.ppat.1000830","volume":"6","author":"S Vinayak","year":"2010","unstructured":"Vinayak S, Alam MT, Mixson-Hayden T, McCollum AM, Sem R, Shah NK, et al. Origin and evolution of sulfadoxine resistant Plasmodium falciparum. PLoS Pathog. 2010;6:e1000830.","journal-title":"PLoS Pathog"},{"key":"3942_CR24","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1016\/S1473-3099(20)30493-X","volume":"21","author":"NK Kayiba","year":"2021","unstructured":"Kayiba NK, Yobi DM, Tshibangu-Kabamba E, Tuan VP, Yamaoka Y, Devleesschauwer B, et al. Spatial and molecular mapping of Pfkelch13 gene polymorphism in Africa in the era of emerging Plasmodium falciparum resistance to artemisinin: a systematic review. Lancet Infect Dis. 2021;21:e82\u201392.","journal-title":"Lancet Infect Dis"},{"key":"3942_CR25","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1086\/649784","volume":"201","author":"C Nsanzabana","year":"2010","unstructured":"Nsanzabana C, Hastings IM, Marfurt J, Muller I, Baea K, Rare L, et al. Quantifying the evolution and impact of antimalarial drug resistance: drug use, spread of resistance, and drug failure over a 12-year period in Papua New Guinea. J Infect Dis. 2010;201:435\u201343.","journal-title":"J Infect Dis"},{"key":"3942_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/tropicalmed4010026","volume":"4","author":"C Nsanzabana","year":"2019","unstructured":"Nsanzabana C. Resistance to artemisinin combination therapies (ACTs): do not forget the partner drug! Trop Med Infect Dis. 2019;4:26.","journal-title":"Trop Med Infect Dis"},{"key":"3942_CR27","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12936-018-2404-4","volume":"17","author":"KM Tun","year":"2018","unstructured":"Tun KM, Jeeyapant A, Myint AH, Kyaw ZT, Dhorda M, Mukaka M, et al. Effectiveness and safety of 3 and 5\u00a0day courses of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in an area of emerging artemisinin resistance in Myanmar. Malar J. 2018;17:258.","journal-title":"Malar J"},{"key":"3942_CR28","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.4269\/ajtmh.16-0483","volume":"95","author":"C Tacoli","year":"2016","unstructured":"Tacoli C, Gai PP, Bayingana C, Sifft K, Geus D, Ndoli J, et al. Artemisinin resistance-associated K13 polymorphisms of Plasmodium falciparum in Southern Rwanda, 2010-2015. Am J Trop Med Hyg. 2016;95:1090\u20133.","journal-title":"Am J Trop Med Hyg"},{"key":"3942_CR29","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/infdis\/jiy223","volume":"218","author":"O Aydemir","year":"2018","unstructured":"Aydemir O, Janko M, Hathaway NJ, Verity R, Mwandagalirwa MK, Tshefu AK, et al. Drug-resistance and population structure of Plasmodium falciparum across the Democratic Republic of Congo using high-throughput molecular inversion probes. J Infect Dis. 2018;218:946\u201355.","journal-title":"J Infect Dis"},{"key":"3942_CR30","doi-asserted-by":"publisher","first-page":"e2100685118","DOI":"10.1073\/pnas.2100685118","volume":"118","author":"HY Ehrlich","year":"2021","unstructured":"Ehrlich HY, Bei AK, Weinberger DM, Warren JL, Parikh S. Mapping partner drug resistance to guide antimalarial combination therapy policies in sub-Saharan Africa. Proc Natl Acad Sci USA. 2021;118:e2100685118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3942_CR31","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1016\/S2666-5247(20)30094-X","volume":"1","author":"HY Ehrlich","year":"2020","unstructured":"Ehrlich HY, Jones J, Parikh S. Molecular surveillance of antimalarial partner drug resistance in sub-Saharan Africa: a spatial-temporal evidence mapping study. Lancet Microbe. 2020;1:e209\u201317.","journal-title":"Lancet Microbe"},{"key":"3942_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12936-019-2645-x","volume":"18","author":"SD Otienoburu","year":"2019","unstructured":"Otienoburu SD, Suay I, Garcia S, Thomas NV, Srisutham S, Bjorkman A, et al. An online mapping database of molecular markers of drug resistance in Plasmodium falciparum: the ACT Partner Drug Molecular Surveyor. Malar J. 2019;18:12.","journal-title":"Malar J"},{"key":"3942_CR33","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1111\/eva.13077","volume":"13","author":"IM Hastings","year":"2020","unstructured":"Hastings IM, Hardy D, Kay K, Sharma R. Incorporating genetic selection into individual-based models of malaria and other infectious diseases. Evol Appl. 2020;13:2723\u201339.","journal-title":"Evol Appl"},{"key":"3942_CR34","doi-asserted-by":"publisher","first-page":"e1002453","DOI":"10.1371\/journal.pmed.1002453","volume":"14","author":"malERA Refresh Consultative Panel on Combination Interventions and Modelling","year":"2017","unstructured":"malERA Refresh Consultative Panel on Combination Interventions and Modelling. malERA: an updated research agenda for combination interventions and modelling in malaria elimination and eradication. PLoS Med. 2017;14:e1002453.","journal-title":"PLoS Med"},{"key":"3942_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12936-015-1075-7","volume":"15","author":"HC Slater","year":"2016","unstructured":"Slater HC, Griffin JT, Ghani AC, Okell LC. Assessing the potential impact of artemisinin and partner drug resistance in sub-Saharan Africa. Malar J. 2016;15:10.","journal-title":"Malar J"},{"key":"3942_CR36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3390\/tropicalmed4040139","volume":"4","author":"C Nsanzabana","year":"2019","unstructured":"Nsanzabana C. Strengthening surveillance systems for malaria elimination by integrating molecular and genomic data. Trop Med Infect Dis. 2019;4:139.","journal-title":"Trop Med Infect Dis"},{"key":"3942_CR37","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12936-019-2784-0","volume":"18","author":"R Dalmat","year":"2019","unstructured":"Dalmat R, Naughton B, Kwan-Gett TS, Slyker J, Stuckey EM. Use cases for genetic epidemiology in malaria elimination. Malar J. 2019;18:163.","journal-title":"Malar J"},{"key":"3942_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ijpddr.2021.07.004","volume":"17","author":"YD Ndiaye","year":"2021","unstructured":"Ndiaye YD, Hartl DL, McGregor D, Badiane A, Fall FB, Daniels RF, et al. Genetic surveillance for monitoring the impact of drug use on Plasmodium falciparum populations. Int J Parasitol Drugs Drug Resist. 2021;17:12\u201322.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"3942_CR39","doi-asserted-by":"publisher","first-page":"e281","DOI":"10.1016\/S1473-3099(20)30939-7","volume":"21","author":"SC Inzaule","year":"2021","unstructured":"Inzaule SC, Tessema SK, Kebede Y, Ogwell Ouma AE, Nkengasong JN. Genomic-informed pathogen surveillance in Africa: opportunities and challenges. Lancet Infect Dis. 2021;21:e281\u20139.","journal-title":"Lancet Infect Dis"},{"key":"3942_CR40","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S1473-3099(13)70252-4","volume":"13","author":"B Witkowski","year":"2013","unstructured":"Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis. 2013;13:1043\u20139.","journal-title":"Lancet Infect Dis"},{"key":"3942_CR41","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1128\/AAC.01868-12","volume":"57","author":"B Witkowski","year":"2013","unstructured":"Witkowski B, Khim N, Chim P, Kim S, Ke S, Kloeung N, et al. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob Agents Chemother. 2013;57:914\u201323.","journal-title":"Antimicrob Agents Chemother"},{"key":"3942_CR42","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12936-018-2185-9","volume":"17","author":"C Nsanzabana","year":"2018","unstructured":"Nsanzabana C, Djalle D, Guerin PJ, Menard D, Gonzalez IJ. Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape. Malar J. 2018;17:75.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03942-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-021-03942-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03942-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T07:34:41Z","timestamp":1634110481000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-021-03942-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,13]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3942"],"URL":"https:\/\/doi.org\/10.1186\/s12936-021-03942-5","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,13]]},"assertion":[{"value":"6 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declares no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"401"}}